Trials / Completed
CompletedNCT04955964
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina
Post Authorization Study to Monitor Efficacy, Effectiveness and Safety of Lanadelumab (Takhzyro®) in Patients Aged 12 Years and Older With Hereditary Angioedema (HAE) in Argentina
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 48 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice. This study is about collecting data only. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. The study will collect data from the participant's medical records. Participants do not need to visit their doctor in addition to their normal visits.
Conditions
Timeline
- Start date
- 2021-07-28
- Primary completion
- 2023-08-07
- Completion
- 2023-08-07
- First posted
- 2021-07-09
- Last updated
- 2023-10-04
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04955964. Inclusion in this directory is not an endorsement.